Pleiotropic effects of statins at the present stage of their study (focus on atorvastatin). Part III. Mechanisms of the pleiotropy of statins

Cover Page

Cite item

Full Text

Abstract

After making a detailed review on the cardiac and non-cardiac pleiotropic effects of statins, the author has attempted to present mechanisms for these effects. The author’s main point is that their non-cardiac pleiotropic effects in diseases of different organs and systems are exposed to statins thanks to the body’s established pathogenic modules that are available in diverse pathologies, including cardiovascular diseases; these are: type 2 diabetes mellitus, obesity, metabolic syndrome, and kidney, liver, and bronchopulmonary system disorders in microbial and viral diseases. In these diseases, the patients are found to have universal pathogenic modules of inflammation, oxidative stress, endothelial dysfunction, hyperangiotensinemia, and inadequate activation of peroxime proliferator-activated receptors. Statins exert an additional positive effect unassociated with their hypolipidemic activity on many of the above pathogenic modules. In most cases, the mechanism of action of statins could be revealed in the above diseases. Special investigations relying on the rules of evidence-based medicine are needed to confirm the found pleiotropic effects.

About the authors

D. M Aronov

State Research Center for Preventive Medicine, Ministry of Health of Russia, Moscow

Email: aronovdm@mail.ru
д-р мед. наук, проф., рук. лаборатории кардиореабилитации ФГБУ ГНИЦ ПМ Минздрава РФ

References

  1. Аронов Д.М. Каскад терапевтических эффектов статинов. Кардиология. 2004; 10: 85–94.
  2. Аронов Д.М., Бубнова М.Г. Плейотропные эффекты статинов на современном этапе их изучения (фокус на аторвастатин). Часть I. CardioСоматика. 2012; 3: 70–81.
  3. Аронов Д.М. Плейотропные эффекты статинов на современном этапе их изучения (фокус на аторвастатин). Некардиальные плейотропные эффекты. CardioСоматика. 2012; 4: 55–63.
  4. Ridker P.M., Silvertown J.D. Inflammation, C-reactive protein, and atherothrombosis. J Periodontol 2008; 79 (Suppl. 8): 1544–51.
  5. Ridker P.M. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; (Suppl. 7) 1: 332–9.
  6. Strey C.H., Young J.M. et al. Short - term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non - ischaemic heart failure. Heart 2006; 92 (11): 1603–99.
  7. Арутюнов Г.П., Карцева Т.П., Воеводина Н.Ю. и др. Влияние агрессивной терапии симвастатином у больных с острым коронарным синдромом и исходно нормальным уровнем ХС ЛПНП на сердечно - сосудистые исходы (ЛАОКООН), пилотное рандомизированное исследование. Тер. Архив. 2005; 9: 53–60.
  8. Link A, Ayadhi T et al. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrom. Eur Heart J 2006; 27: 2945–55.
  9. Fichtischerer S, Schmidt-Lucke C et al. Differential effects of shot - term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD clinical evidence for «pleotropic» functions of statin therapy. Eur Heart J 2006; 27 (10): 1182–90.
  10. Eto M, Rathgeb L, Cosentino F et al. Statins blunt thrombin - induced down - regulation of endothelial nitric oxide synthase expression in human endothelial cells. J Cardiovasc Pharmacol 2006; 45 (5): 663–7.
  11. Morrow D.A., de Lemos J.A. et al. Clinical relevance of C - reactive protein during follow - up of patients with acute coronary syndromes in the Aggrastat - to - Zocor Trial. Circulation 2006; 25 (114): 281–8.
  12. Muhlestein J.B., Anderson J.L., Horne B.D. et al. Intermountain Heart Collaborative Study Group. Early effects of statins in patients with coronary artery disease and high C-reactive protein. Am J Cardiol 2004; 94 (9): 1107–12.
  13. Fruchart J.C. Handbook of dyslipidemia and atherosclerosis. Elsevier Science Limited 2002.
  14. Mc Carey D.W., Mc Innes I.B., Madhok R, Hampson R. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double - blind, randomized placebo - controlled trial. Lancet 2004; 363 (9426): 2015–21.
  15. Титов В.Н., Попкова Т.В., Новикова Д.С. и др. Сравнительный анализ противовоспалительного эффекта аторвастатина при ИБС и ревматоидном артрите. Кардиология. 2008; 48 (9): 4–8.
  16. Wagner A.H., Krzesz R, Gao D et al. Decoy oligodeoxynucleotide characterization of transcription factors controlling endothelin - B receptor expression in vascular. Mol Pharmacol 2000; 58 (6): 1333–40.
  17. Sumi D, Hayashi T, Thakur N.K. et al. A HMG - CoA reductase inhibitor possesses a potent antiatherosclerosis effect other than serum lipid lowering effects – the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001; 155 (2): 347–57.
  18. Rikitake Y, Kawashima S et al. Anti - oxidative properties of fluvastatin, an HMG - CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterolfed rabbits. Atherosclerosis 2001; 154 (1): 87–96.
  19. Di Corleto P.E. et al. Vascular endothelium. In: Atherosclerosis and Coronary Artery Disease I. Eds. Fuster, Ross, Topor. Lippincott - Raven Publishers 1996; p. 378.
  20. Chisolm G.M. et al. Oxidized lipoproteins and atherosclerosis. In: Atherosclerosis and Coronary Artery Disease. Eds. Fuster, Ross, Topor. Lippincott-Raven Publishers 1996.
  21. Galle J, Hansen-Hagge T et al. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 2006; 7.
  22. Giroux L.M., Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low - density lipoproteins by activated human monocyte - derived macrophages. Biochim Biophys Acta 1993; 1165 (3): 335–8.
  23. Петрищев Н.Н. Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция. Спб.: Изд - во СпбГМУ, 2003.
  24. Ushiyama T, Atsuta H, Utsugi N et al. Simvastatin induced heat shock factor 1 in vascular endothelial cells. Atherosclerosis 2006; 188 (2): 265–73.
  25. Igarashi J, Miyoshi M et al. Statins induce S1P (1) receptors and enhance endothelial nitric oxide production in response to high - density lipoproteins. Br J Pharmacol 2007; 15.
  26. Hofnagel O, Luechtenborg B et al. Pravastatin inhibits expression of lectin - like oxidized low - density lipoprotein receptor - 1 (LOX-1) in Watanabe heritable hyperlipidemic rabbits: a new pleiotropic effect of statins. Arterioscler Thromb Vasc Biol 2006; 26 (3): 604–10.
  27. Ushiroyama T, Nosaka S, Ueki M. Short - term effects of low - dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women. Int J Cardiol 2006; 26 (113): 66–75.
  28. Chen X, Ren Z, Liang W, Zha D et al. c-Abl mediates angiotensin II - induced apoptosis in podocytes. J Mol Histol 2013.
  29. Jia J, Ding G, Zhu J Chen C et al. Angiotensin II infusion induces nephrin expression changes and podocyte apoptosis. Am J Nephrol 2008; 28 (3): 500–7.
  30. Liu Y, Hitomi H, Diah S, Deguchi K. Roles of Na+/H+ Exchanger Type 1 and Intracellular pH in Angiotensin II - induced Reactive Oxygen Species Generation and Podocyte Apoptosis. J Pharmacol Sci 2013.
  31. Yoshida T, Tabony A.M., Galvez S, Mitch W.E. et al. Molecular mechanisms and signaling pathways of angiotensin II induced muscle wasting: Potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol 2013. Pii: s1357–2725 (13): 00179–9.
  32. Sodhi K, Puri N, Hyun Kim D et al. PPAR - delta binding to heme oxygenase 1 promoter prevents angiotensin II induced adipocyte dysfunction in goldblatt hypertensive rats. Int J Obes (Lond) 2013.
  33. Ren M, Hao S, Yang C, Zhu P et al. Angiotensin II regulates collagen metabolism through modulating tissue inhibitor of metalloproteinase - 1 in diabetic skin tissues. Diab Vasc Dis Res 2013.
  34. Gopi V, Parthasarathy A, Umadevi S, Vellaichamy E. Angiotensin-II down - regulates cardiac natriuretic peptide receptor - A mediated anti - hypertrophic signaling in experimental rat hearts. Indian J Exp Biol 2013; 51 (1): 48–55.
  35. Park J.K., Müller D.N., Mervaala E.M. et al. Cerivastatin prevents angiotensin II - induced renal injury independent of blood pressure - and cholesterol - lowering effects. Kidney Int 2000; 58 (4): 1420–30.
  36. Bi X.Y., He X, Zhao M et al. Role of endothelial nitric oxide synthase and vagal activity in the endothelial protection of atorvastatin in ischemia/reperfusion injury. J Cardiovasc Pharmacol 2013; 61 (5): 391–400.

Copyright (c) 2013 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies